OTCMKTS:LXRP Lexaria Bioscience (LXRP) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free LXRP Stock Alerts $0.22 -0.03 (-10.68%) (As of 01/11/2021) Add Compare Share Share Today's Range$0.21▼$0.2550-Day Range$0.22▼$0.2252-Week Range$0.17▼$0.56Volume2.15 million shsAverage Volume608,350 shsMarket Capitalization$20.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Lexaria Bioscience alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Lexaria Bioscience Stock (OTCMKTS:LXRP)Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.Read More LXRP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXRP Stock News HeadlinesApril 16, 2024 | msn.comLexaria gets ethics board okay for oral GLP-1 studyMarch 27, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot StudyApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 14, 2024 | msn.comLexaria appoints Nelson Cabatuan as CFOMarch 11, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 GrowthFebruary 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | msn.comWhy Lexaria Bioscience (LEXX) Shares Are MovingJanuary 16, 2024 | finance.yahoo.comLexaria Unveils Extensive Planned 2024 GLP-1 Study ProgramApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.January 11, 2024 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamNovember 30, 2023 | msn.comLEXX: GLP-1s’ Sweet OpportunityNovember 1, 2023 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceOctober 18, 2023 | markets.businessinsider.comLexaria Bioscience’s Growth Prospects: New Licensing Agreement, Advanced Core Pipeline, and Positive Clinical TrialsOctober 13, 2023 | finance.yahoo.comLexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSynAugust 5, 2023 | msn.comLexaria Bioscience (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery SectorAugust 2, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBDJuly 29, 2023 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine StudyJuly 28, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 28, 2023 | finance.yahoo.comLexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 19, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch ProductsMay 10, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting ResultsMay 10, 2023 | finance.yahoo.comLexaria Announces 2023 Annual Meeting ResultsMay 9, 2023 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Announces Dosing Completed on Human Nicotine StudyMay 9, 2023 | investorplace.comWhy Is Lexaria Bioscience (LEXX) Stock Down 27% Today?May 8, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as PlannedMay 8, 2023 | finance.yahoo.comLexaria’s Human Clinical Nicotine Study Completes Dosing as PlannedApril 25, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension StudySee More Headlines Receive LXRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Metal Mining Sub-IndustryN/A Current SymbolOTCMKTS:LXRP CUSIP52886N208 CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,090,000.00 Net Margins-1,046.77% Pretax MarginN/A Return on Equity-157.62% Return on Assets-148.09% Debt Debt-to-Equity Ratio0.01 Current Ratio8.52 Quick Ratio8.01 Sales & Book Value Annual Sales$380,000.00 Price / Sales53.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book7.50Miscellaneous Outstanding Shares89,587,000Free FloatN/AMarket Cap$20.15 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Christopher A. Bunka (Age 58)Chairman & CEO Comp: $300.8kMr. John M. Docherty (Age 51)Pres & Director Comp: $242.52kMr. Allan Spissinger C.A. (Age 51)CPA, CFO, Corp. Sec. & Treasurer Comp: $121.66kVanessa CarleHead of LegalDr. Philip AinslieAdvisor & ConsultantKey CompetitorsPoxelOTCMKTS:PXXLFETAO InternationalNASDAQ:ETAOStreamline Health SolutionsNASDAQ:STRMLumos PharmaNASDAQ:LUMOAptose BiosciencesNASDAQ:APTOView All Competitors LXRP Stock Analysis - Frequently Asked Questions How have LXRP shares performed in 2024? Lexaria Bioscience's stock was trading at $0.2249 at the start of the year. Since then, LXRP shares have increased by 0.0% and is now trading at $0.2249. View the best growth stocks for 2024 here. What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexaria Bioscience investors own include Aurora Cannabis (ACBFF), Organigram (OGI), Cronos Group (CRON), Aphria (APHQF), CV Sciences (CVSI), Auxly Cannabis Group (CBWTF), iAnthus Capital (ITHUF), Alibaba Group (BABA) and GW Pharmaceuticals (GWPH). How do I buy shares of Lexaria Bioscience? Shares of LXRP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:LXRP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
